What is the Share Price of Morepen Laboratories Ltd?
- Answer Field
-
The share price of Morepen Laboratories Ltd for NSE is ₹ 60.17 and for BSE is ₹ 60.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, MOREPEN LAB. LTD share price is currently at ₹ 60.17, which is down by ₹ -2.46 from its previous closing. Today, the stock has fluctuated between ₹ 59.61 and ₹ 62.73. Over the past year, MOREPEN LAB. LTD has achieved a return of 20.21 %. In the last month alone, the return has been 21.85 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 403.25 |
Operating Expense | 377.76 |
Net Profit | 22.69 |
Net Profit Margin (%) | 5.62 |
Earnings Per Share (EPS) | 0.41 |
EBITDA | 36.46 |
Effective Tax Rate (%) | 25.31 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.46 | 19.60 | 1.99 | 279.41 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 119.00 | 15.60 | 1.24 | 1253.91 | 92.25 / 184.95 |
CIPLA LTD | 1549.65 | 25.08 | 4.41 | 125155.99 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 260.70 | 21.60 | 2.64 | 767.27 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|
In the second quarter of fiscal year 2024-25, Morepen Laboratories Limited reported a consolidated net profit of ₹21.26 crore, marking a 45% increase from ₹14.63 crore in the previous quarter. Revenue from operations rose by 5.2% quarter-on-quarter to ₹421.77 crore. The company's EBITDA margin improved to 12.25%, reflecting enhanced operational efficiency. These robust financial results have positively influenced the Morepen Lab share price, reflecting increased investor confidence.
The 2023-24 annual report of Morepen Laboratories Limited provides comprehensive insights into its financial performance and strategic initiatives. The company achieved a total income of ₹1,744.6 crore, registering a growth of 7.7% from the previous year. The report highlights Morepen's focus on expanding its product portfolio, enhancing operational efficiency, and implementing cost optimisation measures. These efforts have contributed to a stable Morepen Laboratories share price by showcasing the company's commitment to growth and profitability.
For the fiscal year 2023-24, Morepen Laboratories Limited declared a total dividend of ₹1.50 per share, reflecting its commitment to returning value to shareholders. This consistent dividend payout, supported by strong financial performance, has positively impacted the Morepen Lab share price by enhancing investor confidence.
1. Who is the CEO of Morepen Lab Ltd?
As of November 2024, the Chairman and Managing Director of Morepen Laboratories Limited is Mr. Sushil Suri. He oversees the company's operations and strategic initiatives, influencing the Morepen Lab share price through effective leadership and business expansion.
2. When was Morepen Lab Ltd established?
Morepen Laboratories Limited was established in 1984. Over the decades, it has grown into one of India's leading pharmaceutical companies, impacting the Morepen Laboratories share price through its extensive operations and market presence.
3. What factors influence Morepen Lab Ltd share price fluctuations?
The Morepen Lab share price is influenced by various factors, including the company's financial performance, product launches, regulatory developments, and broader economic conditions. Additionally, market demand for pharmaceutical products, competition, and research and development outcomes play significant roles in determining share price movements.
4. Is Morepen Lab debt free?
No, Morepen Laboratories Limited is not entirely debt-free. The company utilises debt financing to fund its capital-intensive projects and expansion plans. However, it maintains a balanced debt-to-equity ratio, ensuring financial stability and the ability to meet its obligations without adversely affecting the Morepen Laboratories share price.
5. What is the CAGR of Morepen Lab share?
Over the past five years, the Compound Annual Growth Rate (CAGR) of Morepen Lab shares has been approximately 15%. This indicates a steady growth in the Morepen Lab share price, reflecting the company's consistent financial performance and strategic initiatives.
6. How has the Morepen Lab share price performed over the past year?
Over the past year, the Morepen Lab share price has experienced fluctuations influenced by market conditions and company performance. As of November 2024, the share price has shown a modest increase compared to the same period last year, reflecting investor confidence in the company's strategic direction and financial health.
Morepen Laboratories Limited is an India-based pharmaceutical company. Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin. The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast. It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L.
The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India. The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally. The company has developed a hi-tech Pharma complex at Morepen Village, Baddi (HP) on 60 acres of land that has various multipurpose pharma facilities for API & finished dosages and a Research Centre.
The company was established in the year 1984. The company has filed 14 patents including 6 international PCT applications. The company has filed an international patent on a new amorphous form of the cholesterol-reducing drug Lipitor (Atorvastatin) that is the largest selling drug in the world. During the year 1991-1992, the company set up the new facilities for bulk manufacture of Cephalexin, 7 ADCA and CIMC Chloride at its existing location. During the year 1992-1993, the company started implementing its expansion plans for manufacture Cephalexin, 7ADCA, CIMC Chloride, Research and Development Block and Formulation unit. The company introduced two latest molecules, Ketrolac Tromethamine and Omeprazole. Also, the company also launched Loratadine and Cisapride.
During the year 1993-1994, the company increased the installed capacity of Bulk Drugs from 162 MT to 245 MT. The company started the commercial production of Ketorolac Tromethamine, which is a potent analgesic. During the year 1994-1995, the company increased the installed capacity of Drugs & Drug Intermediates from 305 MT to 469 MT.
During the year 1995-1996, the company successfully launched high value and high technology products namely, Cisapride & Loratadine. Also, the company launched herbal product namely Paclitaxel, an anti cancer drug. During the year 1996-1997, the company commissioned its own formulation unit, which gave a competitive edge to the company in terms of quality and cost efficiency.
During the year 2000-2001, the company increased the installed capacity of Drugs & Drug Intermediates from 916 MT to 1170 MT. The company signed a joint venture with DiaMed AG of Switzerland, a proven international leader in blood group serology diagnostic products. Also, the company developed and launched wide range of contemporary, lifestyle oriented FMHG (Fast Moving Health Goods) Self Medication products.
During the year 2001-2002, the company increased the installed capacity of Drugs & Drug Intermediates from 1170 MT to 1251 MT. Also, the company further increased installed capacity of Tablets / Capsules from 25080 Nos to 35000 Nos. During the year 2004-2005, the company developed the new polymorphic from V1 and field patent in 33 countries and in the same year, the company started finalizing marketing partner for filing ANDA's for the molecule.
During the year 2005-2006, the company made 52 DMF filing across ten European countries for six products. Also, the company broadened its offering by introduced new product like Ducal, Rythmix, Montelast, Alcoflam, Levopen, Moezole, and Cefpen-S.
During the year 2006-2007, the company improved its presence in the key market of South East Asia, Africa & Australia. During the year, the company acquired more than fifty new prospective customers in Korea, Japan, and Taiwan. During the year, the company started of OTC formulation under the umberalla brand 'Dr. Morepen'.
During the year 2007-2008, the company made the tie ups with several new business segments. Marketing alliance with World leaders like lmmucor, USA (for immuunohematology system & consumables), Teco Medical Instruments, Germany (for coagulation system & consumables), InTec INC. (for ELISA Kits), Access Bio, USA (for Rapid Malaria Kits), helped the diagnostics division to make deeper inroads into both the consumer market and the blood bank and laboratory segment.
In 2010, it launched Cardia Division for Diabetic and Cardiac products. In 2015, it started personal Grooming Division with brand GUBB USA. In 2019, it launched APIs for many anti-diabetic molecules. The Company launched 'IntebactImun' in boosting immunity of adults and kids in 2023. It started manufacturing two more products viz., Blood Pressure Monitors and Pregnancy Testing Kits in 2023.
The share price of Morepen Laboratories Ltd for NSE is ₹ 60.17 and for BSE is ₹ 60.
The market cap of Morepen Laboratories Ltd for NSE is ₹ 30,75.70 Cr. and for BSE is ₹ 30,67.01 Cr. as of now.
The 52 Week High and Low of Morepen Laboratories Ltd for NSE is ₹ 100.90 and ₹ 42.00 and for BSE is ₹ 100.80 and ₹ 41.66.
You can trade in Morepen Laboratories Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 20.21%.
Morepen Laboratories Ltd share price is for NSE ₹ 60.17 & for BSE ₹ 60 as on Apr 30 2025 03:30 PM.
The market cap of Morepen Laboratories Ltd for NSE ₹ 30,75.70 & for BSE ₹ 30,67.01 as on Apr 30 2025 03:30 PM.
As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Morepen Laboratories Ltd share is 25.45.
As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Morepen Laboratories Ltd share is 20.95.
You can trade in Morepen Laboratories Ltd shares with Bajaj Broking by opening a demat account.
To buy Morepen Laboratories Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Morepen Laboratories Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found